We believe that one of our key competencies is the ability to integrate and combine in-depth industry, technology and market analyses with valuation and licensing of drugs, diagnostics and devices.

It is difficult to measure this competence in any quantitative way, but it is a combination of educational background, talent and experiences. We have deliberately tried to develop this skill since we are convinced that it is extremely critical to success in life science.

The biotech and life science environment is complex and dynamic. Having a thorough and up to date understanding of the scientific and commercial elements of your projects and the ability to continuously analyze the technology and markets, draw conclusions and take the right decisions in time - makes the difference between failure and success, between loss and profit.

The results speak for themselves. See our cases and references.

Valuation

Wiborg offers valuation of life science assets as one of our services. We do discounted cash flow analysis in most of our valuations and benchmark our findings to the most relevant comparables.

Valuation of life science assets such as R&D projects, technologies and companies, is a rational and meaningful exercise. But only if great care is taken in determining the input parameters and assumptions on which the valuation are based. As part of a valuation of your assets, we  will be very clear  on what are the underlying estimates and assumptions. Furthermore, you will know how the value changes if the estimates change.

All key results are presented in easy-to-communicate Powerpoint slides.

NPV and rNPV

Knowing the best possible estimate of your asset's value and the key value drivers will help you prepare a negotiation strategy and strengthen your negotiation position. The two most commonly used valuation methods are both based on discounting of future cash flows. They only differ in the way they account for risk. In the Net Present Value (NPV) method, all risk is accounted for by the applied "interest" rate (discount factor) whereas technical risk is dealt with separately in the risk-adjusted Net Present Value (rNPV or eNPV) method.

The NPV and rNPV methods both allow for an open discussion of the valuation input parameters and assumptions and both provide detailed insight into the most important value drivers.

In contrast to the NPV and rNPV methods,benchmarkingis a pricing method and not formally a valuation method. While NPV and rNPV-based valuations are preferred by industry professionals, benchmarking is preferred by many investors.

At Wiborg, we are highly experienced at performing both NPV and rNPV-based valuations and at estimating a price based on benchmarking versus disclosed deals. Please refer to the section on valuation services for further information.